Friday , October 7 2022

This blood test would detect Alzheimer's 20 years ago



[ad_1]

Robert Kneschke / Shutterstock.com

American researchers have developed a blood profile that would accurately identify people who may develop Alzheimer's disease years before the onset of symptoms. We tell you more about this promising process.

This test will facilitate the development of new treatments

The most common cause of dementia, the disease ofAlzheimer's affects more than 900,000 people France, mainly people over 65, and millions around the world. If there is currently no cure to stop the progression of the disease, being able to care for people too early to develop it would allow researchers to accelerate research into dementia. Recently scientists have taken a first step in this direction by developing a blood profile to identify patients likely to develop up to 20 years before the onset of symptoms.

Analyzing the levels of beta-amyloid, one of the proteins involved in the onset of the disease, in the blood to predict its accumulation in the brain, the researchersUniversity of Washington believe that a reliable diagnosis can be made years before patients begin to suffer from memory loss. Presented in the newspaper Neurologythe study included 158 adults over 50 years of age, and was found to be fair in 88% of cases, promising figures according to experts, which will still need to be confirmed by larger studies.

94% reliable when combined with two other risk factors

Combining the levels achieved with two other risk factors for the disease (age 65+ and subjects with a genetic variant called SUPPORT4tripling the risk of the disease) this time the blood test proved reliable at 94%. This method will notably allow researchers to recruit participants more easily to clinically test different drugs. Until recently, the method used to assess beta-amyloid levels in the brain was positron emission tomography, which was very expensive and complicated to implement on a large scale.

According to the Dr. James Pickett, a member of theAlzheimer's Society : " This trial will accelerate research on dementia by making it much easier to identify people who may be developing Alzheimer's disease, which may be appropriate for clinical trials to prevent or delay the development of the disease. For its part, the Dr. Imarisio, a specialist in the disease, said: " Improving the accuracy of blood tests has long been a goal for researchers, and using additional genetic risk information to support this test is a brave step forward. The

[ad_2]
Source link